Pfizer PFE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 292.1%+36.2pp | 255.9%-2.4pp | 258.4%+4.2pp | 254.1%-21.4pp | |
| Efficiency | |||||
| Asset turnover | 1.2×+0.1× | 1.1×-0.4× | 1.5×-0.7× | 2.2×+0.7× | |
| Inventory turnover | 25.6×+0.7× | 24.8×-7.3× | 32.2×-73.0× | 105.2×+17.3× | |
| Liquidity | |||||
| Current ratio | 4.9×+0.8× | 4.1×-2.7× | 6.8×+1.2× | 5.6×0.0× | |
| Quick ratio | 4.6×+0.8× | 3.8×-2.5× | 6.3×+0.9× | 5.4×-0.2× | |
| Cash ratio | 0.2×+0.1× | 0.1×-0.2× | 0.3×+0.2× | 0.1×-0.1× | |
| Leverage | |||||
| Debt-to-equity | 2.8×+0.1× | 2.8×+0.4× | 2.4×+0.8× | 1.6×-0.5× | |
| Debt-to-assets | 1.2×+0.1× | 1.1×+0.1× | 1.1×+0.3× | 0.8×-0.2× | |
| Per Share | |||||
| Book value per share | $62.74-0.8% | $63.25-6.6% | $67.72+8.4% | $62.47+22.0% | |
| Valuation | |||||
| Market capitalization | $568.37B-9.7% | $629.58B-20.0% | $786.82B-29.7% | $1.12T+12.4% | |
| Enterprise value | $814.65B-6.8% | $874.52B-13.1% | $1.01T-20.1% | $1.26T+9.9% | |
| Price / sales | 9×-1.7× | 10.7×+0.2× | 10.5×-0.9× | 11.4×-4.6× | |
| Price / book | 6.3×-0.6× | 7×-1.1× | 8.1×-4.5× | 12.6×-1.0× | |
| EV / sales | 13×-1.9× | 14.9×+1.3× | 13.5×+0.7× | 12.8×-5.7× | |
| Dividend yield | 27.2%+3.3pp | 23.9%+5.0pp | 18.9%+6.1pp | 12.8%-1.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Pfizer's ratios come from?
- Every ratio is computed from Pfizer's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
